Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in  hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function

Sodium-glucose cotransporter 2 (SGLT2) inhibitors prevent coupled glucose and sodium reabsorption in the proximal tubule. This leads to glucosuria and lowering of plasma glucose concentrations in people with type 1 diabetes (T1D) and type 2 diabetes (T2D). Additional beneficial effects of SGLT2 inhibitors include reductions in body weight, blood pressure, and plasma uric acid concentrations.1,2 In people with T2D with and without diabetic kidney disease, SGLT2 inhibition improves hard renal outcomes in large-scale clinical trials.

Source: Kidney International - March 19, 2020 Category: Urology & Nephrology Authors: Erik J.M. van Bommel, Yuliya Lytvyn, Bruce A. Perkins, Nima Soleymanlou, Nora M. Fagan, Audrey Koitka-Weber, Jaap A. Joles, David Z.I. Cherney, Dani ël H. van Raalte Tags: Editorial Source Type: research